Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + paclitaxel albumin-stabilized nanoparticle formulation + bevacizumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
A three-drug anticancer regimen combining the platinum agent carboplatin, the taxane paclitaxel delivered as an albumin-stabilized nanoparticle formulation (nab-paclitaxel, brand Abraxane), and the anti-angiogenic monoclonal antibody bevacizumab. Nab-paclitaxel stabilizes microtubules to inhibit mitosis; albumin-mediated transport can enhance paclitaxel delivery and avoids Cremophor solvent reactions. Carboplatin forms DNA crosslinks causing apoptosis. Bevacizumab binds vascular endothelial growth factor A (VEGF-A) to inhibit tumor angiogenesis. This combination has been studied as first-line therapy in advanced non-squamous non-small cell lung cancer, showing promising response rates and manageable toxicity in phase II and I/II studies, and is used in protocols across tumor types where bevacizumab with platinum-taxane backbones are appropriate.[2][1][3][6]
- Brand names
- Abraxane
- Other names
- carboplatin + nab-paclitaxel + bevacizumab
02
Targets
Beyond the preview
Go deeper on carboplatin + paclitaxel albumin-stabilized nanoparticle formulation + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + paclitaxel albumin-stabilized nanoparticle formulation + bevacizumab.